Company: SYRA
Filing Date: 2025-03-11
Form Type: 10-K
Source: 0001493152-25-009873
Chunk: 165

Company: Syra Health Corp
Filing Date: 2025-03-11
Form: 10-K
Item: Item 1
Chunk 165
---
-K, and other filings with the United States Securities
and Exchange Commission, or the SEC, and all amendments to these filings, are available, free of charge, on our website at www.Hepion.com
as soon as reasonably practicable following our filing of any of these reports with the SEC. You can also obtain copies free of charge
by contacting our Investor Relations department at our office address listed above. The public may read and copy any materials we file
with the SEC at the SEC’s Public Reference Room at 100 F Street NE, Room 1580, Washington, DC 20549. The public may obtain information
on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains an Internet site that contains
reports, proxy, and information statements, and other information regarding issuers that file electronically with the SEC at www.sec.gov.
The information posted on or accessible through these websites is not incorporated into this filing.

-7-

ITEM
1A. RISK FACTORS

An
investment in our securities involves a high degree of risk. You should carefully consider the risks described below as well as the other
information included in this Annual Report on Form 10-K, including “Information Regarding Forward-Looking Statements,” “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” and the financial statements and the related notes thereto
included elsewhere in this Annual Report on Form 10-K, before making an investment decision. Our business, prospects, financial condition,
or operating results could be harmed by any of these risks, as well as other risks not currently known to us or that we currently consider
immaterial. The trading price of our securities could decline due to any of these risks, and, as a result, you may lose all or part of
your investment.

Risks
Related to Our Financial Position and Need for Additional Capital

Although
we have generated approximately $8.0 million and $5.5 million of revenues for the years ended December 31, 2024 and 2023, respectively,
our future profitability is uncertain.

Our
likelihood of success must be considered in light of the problems, expenses, difficulties, complications, and delays frequently encountered
in connection with the development and expansion of a business enterprise. Our net losses were $3,759,238 and $2,938,343 for the years
ended December 31, 2024 and 2023, respectively, and our accumulated